Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials by Morvan, Claire et al.
Environmental fatty acids enable emergence of infectious
Staphylococcus aureus resistant to FASII-targeted
antimicrobials
Claire Morvan, David Halpern, Ge´rald Ke´nanian, Constantin Hays, Jamila
Anba-Mondoloni, Sophie Brinster, Sean Kennedy, Patrick Trieu-Cuot, Claire
Poyart, Gilles Lamberet, et al.
To cite this version:
Claire Morvan, David Halpern, Ge´rald Ke´nanian, Constantin Hays, Jamila Anba-Mondoloni, et
al.. Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant
to FASII-targeted antimicrobials. Nature Communications, Nature Publishing Group, 2016, 7,
pp.12944. <pasteur-01385175>
HAL Id: pasteur-01385175
https://hal-pasteur.archives-ouvertes.fr/pasteur-01385175
Submitted on 20 Oct 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution 4.0 International License
ARTICLE
Received 27 Sep 2015 | Accepted 16 Aug 2016 | Published 5 Oct 2016
Environmental fatty acids enable emergence of
infectious Staphylococcus aureus resistant to
FASII-targeted antimicrobials
Claire Morvan1,w, David Halpern1, Ge´rald Ke´nanian1, Constantin Hays2,3,4,5, Jamila Anba-Mondoloni1,
Sophie Brinster2,3,4,w, Sean Kennedy6,w, Patrick Trieu-Cuot7,8, Claire Poyart2,3,4,5, Gilles Lamberet1,
Karine Gloux1 & Alexandra Gruss1
The bacterial pathway for fatty acid biosynthesis, FASII, is a target for development of new
anti-staphylococcal drugs. This strategy is based on previous reports indicating that self-
synthesized fatty acids appear to be indispensable for Staphylococcus aureus growth and
virulence, although other bacteria can use exogenous fatty acids to compensate FASII
inhibition. Here we report that staphylococci can become resistant to the FASII-targeted
inhibitor triclosan via high frequency mutations in fabD, one of the FASII genes. The fabD
mutants can be conditional for FASII and not require exogenous fatty acids for normal growth,
and can use diverse fatty acid combinations (including host fatty acids) when FASII is
blocked. These mutants show cross-resistance to inhibitors of other FASII enzymes and are
infectious in mice. Clinical isolates bearing fabD polymorphisms also bypass FASII inhibition.
We propose that fatty acid-rich environments within the host, in the presence of FASII
inhibitors, might favour the emergence of staphylococcal strains displaying resistance to
multiple FASII inhibitors.
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S
taphylococcus aureus is a remarkably versatile opportunist
pathogen that has confounded the medical community by
its ability to escape antibiotic inhibition. Multidrug-resistant
S. aureus are a main cause of hospital- and community-acquired
infections, and treatment constitutes a major medical and
economic challenge1,2. The fatty acid synthesis pathway (FASII)
has been a leading candidate as a novel essential target for
antimicrobial discovery. Numerous FASII inhibitors are in the
pipeline or in clinical trials, most of which target FabI, the enoyl-
acyl carrier protein (ACP) reductase (for example, AFN-1252
(now Debio-1452 and pro-drug Debio-1450), CG400549,
CG400462 and MUT056399), or FabF, the b-ketoacyl-ACP
synthase (for example, platencin, platensimycin and fasamycins
A and B)3–11.
Triclosan, a chemically synthesized biocide ﬁrst introduced in
1965, is the best known FabI inhibitor developed thus far, and has
had widespread use in hygiene, health care, and household
products at concentrations of up to 1% (refs 12,13). In
consequence, triclosan detection in human ﬂuids is common,
and has generated information on the limits of use of this
anti-FASII, including safety issues14–19. Observed side effects
of triclosan on the host may be caused by its general
membrane-disrupting activity12,17,19. Additionally, triclosan-
resistant staphylococci, conferred by mutations that maintain
FASII activity, or obtained by horizontal transfer of the
Staphylococcus haemolyticus fabI gene (encoding a naturally
occurring resistant FabI variant), are estimated to comprise
5–15% of S. aureus clinical isolates14,16,20. Continued anti-FASII
development is based on development of antimicrobials with
greater FabI afﬁnity and speciﬁcity that would curb its potentially
dangerous side effects4,9,21–24.
However, fatty acids are abundant in the host and can be used
by several Gram-positive pathogens to overcome a FASII
deﬁciency25–28, which questions FASII targeting as a general
strategy for antibacterial drug discovery. For example, exogenous
fatty acids can fully compensate a FASII deﬁciency in
Streptococcus agalactiae, and a FASII auxotroph was fully
virulent in a murine septicaemic infection model25.
Nevertheless, the ability of S. aureus to override FASII
inhibition in the presence of fatty acids has remained in
question4,21,26,29,30. S. aureus FASII expression is not blocked
by exogenous fatty acids, whereas it is inhibited in streptococci21.
Rather than synthesizing unsaturated fatty acids to ﬂuidify their
membranes (as do the streptococci), S. aureus synthesizes
branched chain fatty acids, of which the main one, anteiso
C15:0 (ai15:0), is apparently required for phospholipid
synthesis27,31,32. Moreover, it has been proposed that FASII
inhibition in S. aureus leads to accumulation of acyl-ACP
intermediates, thereby limiting ACP availability for exogenous
fatty acid utilization9,27,33,34 (see Supplementary Figs 1 and 2 for
pathway and genetic contexts). In addition, while fatty acid
auxotrophs (defective in acc genes encoding acetyl-CoA
carboxylase) are viable, optimal growth requires ai15:0, and
these acc mutants are avirulent in a mouse septicaemic infection
model24,27,32.
The fundamental and medical importance of FASII-targeted
drug development incited us to characterize S. aureus responses
to anti-FASII drugs. Here we show that fatty acids, which are
ubiquitous host constituents, can facilitate the emergence of
S. aureus resistance to anti-FASII drugs.
Results
Fatty acids facilitate the emergence of triclosan resistance.
Some Gram-positive bacteria can incorporate exogenous fatty
acids, which enable resistance to anti-FASII drugs25,26. In the case
of S. aureus, we considered the possibility that arising mutations
could facilitate fatty acid incorporation and lead to FASII bypass,
as hypothesized in an earlier study27. To reveal such fatty-acid-
based triclosan resistant (FA-TR) mutants, we examined the
response of the S. aureus Newman strain to the FabI inhibitor
triclosan on fatty-acid-containing BHI solid medium. A fatty acid
cocktail (referred hereafter as ‘FA’) was used comprising C14:0,
C16:0, and C18:1, which are present in the human host35,36.
Overnight S. aureus BHI cultures were plated on medium
containing FA and 0.25 mgml 1 triclosan; as controls, they were
also plated on medium without FA and/or triclosan. Triclosan-
resistant colonies arose at about 100-fold higher frequencies
(B10 6) in the presence of FA. The FA-TR colonies were
screened for growth on BHI, BHI-triclosan (BHI-T), BHI-FA and
BHI-FA-triclosan (BHI-FA-T) plates (Supplementary Fig. 3). A
minority of clones grew on all four media (FA prototroph
triclosan resistant mutants, TR mutants). The remaining clones
grew either on BHI, BHI-FA and BHI-FA-T (FA prototrophs), or
on FA-containing media but very poorly or not at all on BHI. The
latter were thus considered as fatty-acid-dependent for normal
growth and were designated DepTR mutants. Fatty acids thus
appear to facilitate the emergence of triclosan resistance in
S. aureus.
Three classes of S. aureus FA-TR mutants. Fatty acid proﬁles of
randomly selected FA-TR mutants (16 prototrophs and 20 DepTR
mutants) were determined from whole cell extracts of cultures
prepared in BHI-FA-T medium. Representative proﬁles of each
class of mutants are shown (Fig. 1). Among prototrophs, a minor
class (3/16) comprised mutants with endogenous (EndoTR) fatty
acid proﬁles, indicating that the FASII pathway was active. The
dominant class of prototrophs (13/16) comprised mutants having
media-dependent fatty acid proﬁles, that is, with exogenous fatty
acids in BHI-FA-T, and endogenous fatty acids in BHI (condi-
tional triclosan-resistant mutants, referred to as CondTR).
Mutants of this class have not previously been reported.
All the DepTR clones showed poor or no growth on BHI plates,
but displayed exogenous proﬁles in BHI-FA-T medium. These
results show that the majority of isolated FA-TR mutants were
able to bypass a FASII block by incorporating exogenous fatty
acids.
Gain of function in an S. aureus conditional mutant. Growth
and fatty acid proﬁles of CondTR-17 and the Newman strain were
compared in the absence or presence of fatty acids and triclosan
(Fig. 2a). Growth of both strains was comparable in BHI medium.
The addition of fatty acids expectedly slowed strain growth,
which was also comparable for both strains (Fig. 2a, centre)37,38.
When triclosan was added, CondTR-17 maintained growth, but
not the Newman strain. Fatty acid proﬁles conﬁrmed CondTR
strain capacity to bypass FASII inhibition and shift to the
exogenous FA source (Fig. 2b). Thus, this conditional mutant can
use exogenous fatty acids upon FASII block, while displaying
normal growth otherwise.
Numerous FASII-bypass mutations map to fabD. Known
S. aureus triclosan-resistant mutants carry mutations in the gene
encoding FabI, the triclosan target: such mutant enzymes fail to
bind triclosan but remain enzymatically active12,14,16,24. Our
FA-TR clones with EndoTR fatty acid proﬁles resembled
previously described strains carrying mutations in fabI14,16. The
role of fatty acids in obtaining such mutants is unknown. In
contrast, all tested mutants with exogenous fatty acid proﬁles
(DepTR and CondTR strains) carried wild type fabI genes
(Table 1).
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Previously isolated S. aureus fatty acid auxotrophs mapped to
FASII initiation genes accC and accD, encoding acetyl-CoA
carboxylase subunits (biotin carboxylase and b-carboxytransfer-
ase respectively) for malonyl-CoA synthesis27 (Supplementary
Fig. 1). Among ﬁve tested DepTR mutants, one (DepTR-28)
carried an accB mutation (Table 1).
Whole genome sequencing of one CondTR and three DepTR
mutants revealed that these mutants carried fabD mutations as
compared with the Newman parental strain (Table 1, sequenced
strains are designated with ‘#’). CondTR-17 bore a single
nucleotide substitution generating FabDG196R; DepTR-5 carried
a single nucleotide insertion that truncated FabD at amino acid
position 8. No other mutation was detected in either strain.
Strains DepTR-45 and DepTR-72 displayed single nucleotide
deletions in fabD, and each carried a second mutated allele
(Table 1), which mapped to either NWMN_0043 encoding
conserved Staphylococcal Antigen 1b (Csa1b), one of a conserved
family of 18 protein homologues39 (for DepTR-45), or
NWMN_1735, encoding a DNA-repair-related protein40 (for
DepTR-72). We chose to focus here on the singly mutated fabD
strains. Sequencing fabD of other FA-TR CondTR clones revealed
mutations mainly at position G196, and one at position Q265
(Table 1). FabD G196 is adjacent to key residues (positions 198
and 199) of the FabD active site based on S. aureus FabD
crystallography41; it is possible that substitution by less ﬂexible
amino acids than glycine might impose constraints on FabD
activity. The Q265P mutation is within a conserved region
separating a helix from a b-strand as suggested from Escherichia
coli FabD structure42.
Thus, the majority of FA-TR S. aureus mutants identiﬁed here
contain mutations in fabD and utilize exogenous fatty acids to
overcome FASII inhibition. Both fabD and acc intervene in FASII
initiation (Supplementary Fig. 1), suggesting the importance of
this ﬁrst step in FASII bypass27.
Diverse fatty acid combinations allow FASII bypass. Previous
studies suggested that ai15:0 was strictly required at the second
acyl position of the S. aureus phospholipid24,27,32,43. However,
our results indicated that other fatty acids can replace ai15:0. We
explored the possibility that a fatty acid of similar length, like
C14:0 (33% of our FA cocktail), might substitute for ai15:0 when
FASII was blocked (Fig. 3). The DepTR-5 mutant was grown in
medium containing triclosan and fatty acid cocktails with 33, 3 or
0% C14:0. For each cocktail, the amounts of C14:0 in S. aureus
proﬁles reﬂected its proportions among fatty acids in the
medium, indicating that C14:0 is not preferentially incorporated
for FASII bypass.
A mix of the four principal fatty acids in human serum in
physiological proportions (C16:0, C18:0, C18:1 and C18:2) was
also tested. When added in puriﬁed form, the free fatty acid
cocktail was toxic to staphylococci, likely due to C18:2 (linoleic
acid), which makes up B35% of serum fatty acids35. However,
growth was restored when 10% delipidated serum was added, and
DepTR-5 displayed an exogenous fatty acid proﬁle (Fig. 3e).
To mimic the within-host environment during infection, we
grew S. aureus wild type and DepTR-5 strains in medium
containing sterile-ﬁltered pig liver and kidney extracts. The
incorporated fatty acids reﬂected those present in the medium
(shown for liver; Fig. 3f, see Supplementary Fig. 4 for organ
extract proﬁle). Unexpectedly, long-chain unsaturated fatty
acids C18:2 and C20:4 were efﬁciently incorporated. C16:0 was
the shortest abundant fatty acid incorporated, indicating that
DepTR-5 fabD mutant growth was not dependent on ai15:0 or
other short-chain fatty acids.
Thus, the S. aureus fabD mutant can use diverse fatty acids,
including those available in the host, and can dispense with
branched chain fatty acids. These results indicate that the
composition of the S. aureus membranes can be more ﬂexible
than generally supposed24,27,32,43.
Role of the S. aureus fabD allele in FASII bypass. To conﬁrm
that the fabD mutation is responsible for fatty acid dependency of
DepTR-5, the wild type fabD gene was cloned in expression vector
pJ (resulting in pJ-fabD) and established in the mutant strain
background. To simulate in vivo conditions and obtain insight
into S. aureus fabD mutant behaviour in the animal host, tests
were performed in medium supplemented with liver and kidney
extracts as fatty acid sources. In non-supplemented medium, the
pJ-fabD plasmid restored ai15:0 synthesis and growth to the
DepTR-5 strain, conﬁrming that the fabD mutation was respon-
sible for the FASII defect (Fig. 4a). Importantly, growth of
DepTR-5 (pJ) in host organ extracts was comparable to that of the
Newman (pJ) strain, indicating that DepTR-5 can grow robustly
while using exclusively host fatty acids. In this condition,
complementation with pJ-fabD also resulted in ai15:0 synthesis
Newman WT
In BHI-FA
In BHI
1
2 3
Elution time (min)
FA-TR mutants
DepTR
CondTR
EndoTR
1
2 3
15 20 25 30
a
b
Figure 1 | S. aureus Newman WTand FA-TR mutants use exogenous fatty
acids. Fatty acid proﬁles are shown for (a) Newman strain (WT) cultures
grown in BHI and BHI-FA and (b) FA-TR clones grown in BHI-FA-T. S. aureus
synthesizes branched chain fatty acids de novo, mainly C15:0 (ai15:0;
indicated by arrow) and its elongation products, and saturated straight
chain fatty acids. In BHI-FA, the WT strain uses exogenous fatty acids, but
continues de novo synthesis. Peaks 1, 2, and 3 correspond to the exogenous
fatty acids added during growth, respectively C14:0, C16:0, and C18:1
(collectively referred to as ‘FA’, see Methods). EndoTR, FA-TR with
endogenous fatty acids (grey); CondTR, FA-TR with conditional FASII
activity (blue), that is, active in BHI but bypassed in fatty acids plus
triclosan; DepTR, FA-TR requiring exogenous fatty acids for growth (red).
The fatty acid proﬁle of the EndoTR mutant was similar to that of the WT
in BHI, while CondTR and DepTR proﬁles are exogenous.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12944 ARTICLE
NATURE COMMUNICATIONS | 7:12944 | DOI: 10.1038/ncomms12944 |www.nature.com/naturecommunications 3
(Fig. 4b). In triclosan plus host organ extracts, growth of DepTR-5
(pJ-fabD) lagged slightly behind that of DepTR-5 (pJ) (Fig. 4c,
Supplementary Fig. 5a). The intermediate effect could indicate
that triclosan exerts a counter-selective effect on the plasmid-
carried fabD copy.
CondTR-17 grew both without and with fatty acid supple-
mentation, and as expected, strong phenotypic differences were
not observed in CondTR-17 complementation tests. The CondTR-
17 (pJ or pJ-fabD) strains grew like Newman (pJ) in host organ
extracts (data not shown). However, as above, CondTR-17
(pJ-fabD) displayed a slight growth retardation compared with
CondTR-17 (pJ) in fatty-acid-triclosan-containing media as
shown in the presence of kidney extracts (Supplementary
Fig. 5b). In view of the absence of other mutations in the
WT
a
BHI-FA-TriclosanBHI
n.g.
1 2 3
15 20 2515 20 25
15 20 25
1
2
3
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O
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Figure 2 | Gain of function of the S. aureus CondTR-17 mutant. (a) Growth of WTand CondTR-17 (fabDG196R) S. aureus strains in BHI, BHI-FA and BHI-FA-T
media. Results show the average and range of biologically independent duplicates. (b) Fatty acid proﬁles of one sample set, taken at the 10 h time point.
Endogenous branched-chain fatty acid (ai15:0) is indicated with arrows. Fatty acids are: 1- C14:0; 2- C16:0 and 3- C18:1, the fatty acids comprised in BHI-FA-
T medium. N.g., no growth. Black, WT; blue, CondTR-17.
Table 1 | Characterization of FA-TR mutants.
Strain Fatty acid
prototroph/dependent*
Fatty acid proﬁle
in FA-Tw
Detected FASII mutation Other mutationsz
Newman# Prototroph – –
EndoTR-62 Prototroph Endo FabIA95V Nt 977098 C-T
EndoTR-41 Prototroph Endo FabII193N Nt 977392T-A
CondTR-1 Prototroph Exo FabDG196V Nt 1250192 G-T
CondTR-4 Prototroph Exo FabDG196V Nt 1250192 G-T
CondTR-7 Prototroph Exo FabDG196V Nt 1250192 G-T
CondTR-83 Prototroph Exo FabDQ265P Nt 1250399A-C
CondTR-17# Prototroph Exo FabDG196R Nt 1250191 G-C None detected
DepTR-5# Dependent Exo FabDTrunc AA8þ 14AA tail Nt 1249630T insertion None detected
DepTR-45# Dependent Exo FabDTrunc AA 285 Nt 1250461A deletion NWMN_1735y Nt 1935749T deletion
DepTR-72# Dependent Exo FabDTrunc AA289þ 3AA tail Nt 1250471A deletion NWMN_0043y Nt 56530 G deletion
DepTR-28 Dependent Exo AccBD25Y Nt 1603874 G-T
DepTR-71 Dependent Exo FabDTrunc AA 147 Nt 1250042 C-A
*Prototrophs retain fatty acid synthesis capacity; in the absence of fatty acids they display endogenous (Endo) proﬁles; in the presence of fatty acids and a FASII inhibitor, they display either endogenous
(Endo) or exogenous (Exo) proﬁles. Fatty-acid-dependent (DepTR) strains rely on exogenous fatty acids under all conditions.
wFatty acid proﬁles were determined from cultures in BHI-FA-T (C14:0, C16:0 and C18:1, 0.17mM each, and 0.25mgml 1 triclosan in BHI medium). # after strain names signify that strains were genome
sequenced.
zOther mutated genes were detected among the genome-sequenced isolates (strains designated with #).
yNWMN_1735 encodes a 978 AA ORF with partial similarity to DNA repair proteins40. A single nucleotide deletion (position 1935749) interrupts the ORF at position 428, adding a 5 AA out-of-frame
tail. NWMN_0043 encodes Conserved Staphylococcal Antigen 1b, Csa1b, one of a conserved family of 18 protein homologues present in the Newman strain39. A single nucleotide deletion (position
56530) truncates the 256 AA ORF after position 82, with a 3 AA out-of-frame tail. All strains exhibiting exogenous fatty acid proﬁles encode wild type fabI loci. Nt, nucleotide; trunc, truncated.
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CondTR-17 strain, the identiﬁcation of other ‘CondTR’ isolates
mutated in fabD (Table 1), and the existence of fabD variants
with FA-TR phenotypes among clinical isolates (below), we
consider that fabDG196R is responsible for the CondTR-17
conditional phenotype.
These results lead us to conclude that the fabD allele is
responsible for the FASII defect in DepTR-5 and CondTR-17
strains. Both mutants grew comparably to the WT strain in host-
simulated conditions, suggesting that these mutants would behave
like the wild type strain in host compartments.
Cross-resistance of S. aureus fabD mutants to FASII inhibitors.
AFN-1252 is a FabI inhibitor in clinical trials44; platensimycin is a
FabF inhibitor and antimicrobial candidate11. Cross-resistance
between triclosan and these drugs was tested. S. aureus Newman
(WT) and fabDmutants DepTR-5 and CondTR-17 were plated on
BHI or BHI-FA media. FabI inhibitors triclosan and AFN-1252,
and the FabF inhibitor platensimycin were spotted on lawns
(at 100, 100 and 16 times the respective minimal inhibitory
concentrations (MIC)) (Fig. 5a–d). Triclosan- and AFN-1252-
resistant colonies appeared within the inhibitory zones of the WT
strain only on fatty-acid-containing plates (compare Fig. 5a,b).
Platensimycin was poorly effective in both media at the tested
concentration. We also noted a pronounced decrease in the
inhibitory zone diameter for triclosan on BHI-FA compared with
BHI plates (compare Fig. 5a,b). In contrast, both DepTR-5 and
CondTR-17 strains grew, albeit more slowly, within inhibitory
zones of the 3 FASII inhibitors on BHI-FA plates (Fig. 5c,d).
Cross-resistance was then checked for colonies isolated from
WT BHI-FA plates as triclosan, AFN-1252 or platensimycin
resistant (Fig. 5b). Colonies were patched on BHI-FA medium
containing triclosan (0.25mgml 1) or AFN-1252 (0.08mgml 1)
(Fig. 5e). Fatty acid proﬁles of colonies as determined on primary
selections and cross-selections were all exogenous (not shown).
In addition, liquid cultures of DepTR-5 and CondTR-17
conﬁrmed the capacity of DepTR-5 and CondTR-17 to grow on
platensimycin and incorporate exogenous fatty acids (Supple-
mentary Fig. 6).
These results further support a role of fatty acids in facilitating
S. aureus escape from anti-FASII inhibition, and show that
mutants selected by the use of a FASII inhibitor can be resistant
to other FASII inhibitors.
Infection by S. aureus fabD mutants. Infections by fabD DepTR-
5, fabD CondTR-17 or the WT strain were compared in a mouse
sepsis model. A low inoculum (106 CFU) was used to avoid the
possibility of false-positive virulence assignments32. The
conditional FA-TR mutant, CondTR-17, was as infective as the
parental Newman strain and gave equivalent CFUs in both liver
and kidneys (Fig. 6). These results indicate that this strain, and
possibly similar variants, can retain full virulence.
The DepTR-5 mutant showed delayed kinetics of infection. At
two days post-infection, signiﬁcantly lower CFUs were present in
both liver and kidneys compared with the WT strain (P¼ 0.001
in both organs using the Mann–Whitney U-test). However, these
differences narrowed at 6 days post-infection, particularly in
kidneys, where DepTR-5 CFUs increased and were not statisti-
cally different from WT CFUs (P¼ 0.77 in kidneys) (Fig. 6).
Colonies issued from the 6-day infection were conﬁrmed to
maintain fatty acid growth dependency, and two colonies selected
at random from each organ were conﬁrmed to carry the original
fabD mutation.
Our results indicate that both CondTR and DepTR mutants
would resist challenge by a FASII inhibitor in vivo. As DepTR-5
and CondTR-17 also proliferate and incorporate fatty acids in the
presence of AFN-1252 and platensimycin (Fig. 5c,d), we speculate
that both types of mutants might override FASII inhibition
regardless of the FASII inhibitor.
FASII bypass in natural isolates carrying FabD polymorphisms.
Our results show that the CondTR-17 G196R substitution
correlates with FASII bypass via incorporation of exogenous fatty
acids. We searched public databases for natural S. aureus isolates
carrying FabD modiﬁcations at the G196 position, and found
three such isolates. Two independent sputum and nare
isolates carry FabDR196: M0251 (a methicillin-resistant S. aureus
(MRSA) clonal complex CC5 isolate, BioSample accession code
SAMN02325289) and M1532 (BioSample accession code
SAMN02364048). The third strain, SA40, is a community- and
epidemic-associated methicillin-resistant sequence type ST59 that
was isolated from a healthy child and carries a FabDS196 protein.
A closely related ST59 strain SA957 is an MRSA blood isolate that
does not carry the FabD196 polymorphism45. These S. aureus
isolates as well as two FATR mutants were tested for their capacity
to bypass FASII. The three strains carrying FabD196
polymorphisms, but not the Newman or SA957 strains, showed
FASII bypass on BHI-FA-T liquid medium, as veriﬁed by growth
and exogenous FA incorporation (Table 2). These results further
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Figure 3 | A S. aureus fabD mutant uses diverse fatty acid combinations
for FASII bypass. (a) Newman strain in BHI. (b–f) Cultures of DepTR-5
were grown in BHI medium supplemented with triclosan and different fatty
acid combinations and ratios, as indicated. Fatty acid proﬁles and OD600
were determined on cells harvested from 7.5 h (a–e) and 4.5 h (f) cultures.
a, medium was supplemented with 10% delipidated serum, which lowered
toxicity. b, Liver extract, prepared by sterile ﬁltration, was added at a ﬁnal
concentration of 3% (without added fatty acids). The diagonal arrow
indicates the position of ai15:0, the major fatty acid synthesized by S. aureus.
Fatty acids are: 1- C14:0; 2- C16:0; 3- C18:1; 4- C18:0; 5- C18:2; 6- C20:4.
Proportions of input fatty acids present in supplemented media are
indicated at left. Fatty acid proﬁle of liver extract is in Supplementary Fig. 4.
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Figure 4 | Complementation of DepTR-5 by the wild type fabD allele. Overnight LB-FA cultures of WTand DepTR-5 strains carrying pJ (control plasmid),
or pJ-fabD (expressing the fabD gene) were washed twice in LB, and cultures were inoculated at a starting OD600¼0.05 in (a) LB (Cm 3mgml 1 and ATc
50 ngml 1), (b) the same medium containing sterile-ﬁltered pig kidney extract (3% ﬁnal volume) without or (c) with triclosan (0.5mgml 1). OD600 was
followed over 8 h. Fatty acid proﬁles were determined from harvested cells, as shown below the corresponding growth condition. N.g., no growth. Reference
fatty acid proﬁle and peak identiﬁcation of kidney extract is in Supplementary Fig. 4. Growth results show the average with standard deviation of three
experiments that gave comparable results (Supplementary Fig. 5). However, despite precautions, growth was variable between independent experiments,
which may be due to the counter-selective effect of triclosan on the pJ-fabD plasmid.
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Figure 5 | S. aureus cross-resistance to anti-FASII drugs in the presence of exogenous fatty acids. Overnight BHI-FA-grown cultures of Newman WT,
DepTR-5, and CondTR-17 were washed twice in BHI and plated on BHI solid medium without (a) (for Newman strain) or with fatty acids (b–d). Plates were
spotted with triclosan (‘T’, 1.5mg), AFN-1252 (‘A’, 1mg), and platensimycin (‘P’, 8mg), respectively 100, 100 and 16 times the MIC. Photographs were taken
after 48 h at 37 C. (c) DepTR-5 and (d) CondTR-17 strains accrue resistance to all three drugs on FA plates as seen by growth within the halo region, as
compared with (b) the WT strain. The small inhibitory zone around triclosan is attributed to non-speciﬁc membrane effects12. (e) colonies that appeared
within the inhibitory zones of WT strains on BHI-FA plates were cross-patched on BHI, BHI-FA, BHI-FA-AFN-1252 (80 ngml 1) and FA-triclosan
(250 ngml 1). All colonies picked in fatty acids as triclosan-resistant were AFN-1252-resistant, and conversely. Fatty acid proﬁles (not shown) determined
for colonies from each anti-FASII selective plate were fully exogenous.
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support the correlation between fabD196 polymorphism and anti-
FASII resistance, and show the capacity of S. aureus human
isolates to use exogenous fatty acids to overcome FASII inhibitors.
They also indicate that anti-FASII-resistance is present in some
commensal and clinical isolates.
Redistribution of acyl-ACP pools in fabD variants. FabD
catalyses the transfer of malonyl from malonyl-CoA to acyl-car-
rier proteins (ACPs), yielding malonyl-ACP (Supplementary
Fig. 1). We considered that FabD polymorphisms near the active
site (that is, position 196) might lower the efﬁciency of this
reaction, thus leaving free ACP available for exogenous fatty acid
incorporation. Two strain pairs were used to test this hypothesis:
Newman strain (fabDG196)–CondTR-17 (fabDR196) and ST59
clinical strains SA957 (fabDG196)–SA40 (fabDS196). Cell extracts
and culture supernatants were prepared from 4 h cultures in
BHI-FA-T. Short- and long-chain acyl-ACP were assessed on
Western blots of conformation-sensitive gels using anti-ACP
antibodies27,46; fatty acid proﬁles of cell extracts were done in
parallel (Fig. 7). A dithiothreitol (DTT)-treated extract of
BHI-grown Newman strain was used to identify the migration
position of free ACP27,46,47.
Acyl-ACP species were redistributed in both fabD variants
(CondTR-17 and SA40) compared with respective reference
strains. Short-chain acyl-ACP pools were decreased in both
variant strains, which is consistent with a reduced FabD activity
as hypothesized. In addition, the fabD mutants contain long-
chain acyl-ACPs that are not detected in reference strains, and
their fatty acid proﬁles (but not those of the reference strains) are
fully exogenous. Certain fatty acids are known to induce ACP
release from S. aureus cells38; however, we found that at 4 h,
supernatants of all strains produced weak signals that did not
differ signiﬁcantly between strain pairs (Supplementary Fig. 7).
Thus, we hypothesize that the FabDR196 and FabDS196 mutant
enzymes may be less active than FabDG196, allowing free ACPs to
be loaded with exogenous long-chain fatty acids that can then be
incorporated into membrane phospholipids.
Discussion
The present work shows that a fatty-acid-rich environment can
favour the emergence of S. aureus strains displaying resistance to
multiple FASII inhibitors. Point mutations in fabD appear to
facilitate FASII bypass by enhancing incorporation of exogenous
fatty acids. Conditional (CondTR) fabD mutants can grow
normally, and can also bypass FASII in the presence of exogenous
fatty acids, which suggests that they might be able to spread
successfully in environments such as host organs. The S. aureus
fabD mutants can use various fatty acid combinations (Fig. 3).
This ﬂexibility indicates that, contrary to previous assump-
tions24,27,43, the branched-chain fatty acid requirement in
S. aureus is not strict, as shown here for fabD196 variants in
laboratory and clinical strains from major lineages (CC8, CC5
and ST59). It may also help survival of anti-FASII-resistant
bacteria in different host compartments that vary in fatty acid
composition. Therefore, we propose that all these factors need to
be considered when developing anti-FASII drugs for treating
S. aureus infection4,5,8,10,11,48,49.
In FASII-bypass conditions, fabD196 variant strains show
decreased levels of short-chain acyl-ACPs and increased levels
of long-chain acyl-ACPs, in comparison with reference strains
(Fig. 7). The decrease in short-chain acyl-ACP is consistent with
our proposal that FabD196 variants may have reduced enzyme
activity. We speculate that the detected long-chain acyl-ACP
species correspond to exogenous fatty-acyl-ACP intermediates in
phospholipid synthesis, which is consistent with the exogenous
fatty acid proﬁles of fabD196 variants (Fig. 7). FASII bypass might
depend on the outcome of competition for ACP between two
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Figure 6 | Infection and persistence of fabD isolates in a mouse model.
Newman WT (black), CondTR-17 (fabD conditional; blue), and DepTR-5
(fabD fatty-acid-dependent; red) strains were prepared. 106 CFU were
injected in the tail veins of 6-week female BALB/c mice (in groups of 8–11).
In these experiments, one WT-infected and one CondTR-17-infected mouse
died 4 days post-infection. At days 2 (D2) and 6 (D6), animals from each
group were sacriﬁced and dissected. Liver and kidney were homogenized by
ultra-turrax and CFU per organ were determined by serial dilutions on BHI-
FA plates containing 10% serum. Results are pooled from two independent
experiments. Statistical tests were done using Mann–Whitney U to
determine differences in CFU between groups on D2 and/or D6. No
signiﬁcant differences were observed between WT and CondTR-17 in any
test condition. Notably, no signiﬁcant difference was observed between
WT and DepTR-5 CFUs in kidneys at D6 (P¼0.77). NS, non-signiﬁcant
differences. The detection limit was 102 CFU per organ; samples with no
CFUs were plotted as ‘0’. In DepTR-5 samples, one mouse showed no
detectable counts in liver or kidney.
Table 2 | Natural clinical isolates bear fabD variants that favour FASII bypass.
Strain Origin FabD196 locus Growth on FA proﬁle on FA-T
BHI FA-T
Newman Clinical-lab FabDG196 þ þ þ þ – –
SA957 Blood FabDG196 þ þ þ þ – –
SA40 Nare FabDS196 þ þ þ þ þ þ þ þ Exo
MO251 Sputum FabDR196 þ þ þ þ þ Exo
MO1532 Nare FabDR196 þ þ þ þ þ þ þ þ Exo
CondTR-4 FATR FabDV196 þ þ þ þ þ þ þ Exo
CondTR-17 FATR FabDR196 þ þ þ þ þ þ þ Exo
The NCBI database was searched for natural S. aureus isolates bearing FabD proteins with residues other than G196. Three such strains were received: CC5 isolate M0251, M1532 (Brigham and Women’s
Hospital, Boston; Mary Delaney and Michael Calderwood), and ST59 strain SA40 a Taiwanese commensal strain (Go¨tz and Stemmler;45). ST59 strain SA957, whose fabD is identical to that of SA40
except for position 196, was used as reference for SA40 (Go¨tz and Stemmler45). All strains listed above were grown overnight in BHI, BHI-FA (not presented) and BHI-FA-T. Overnight OD600:
þ þ þ þ ¼8 or above; þ þ þ ¼ 3–7.9; þ þ ¼ 1 to 2.9; þ ¼0.5–1;  ¼ no growth. Growth results were within this range in three biological replicates. Fatty acid proﬁles for all strains but Newman
and SA957 were determined on BHI-FA-T. FA, fatty acid; FA-T, BHI-FA-Tmedium. Exo, exogenous fatty acid proﬁle.
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enzymes at opposing ends of the pathway: the FASII initiation
enzyme FabD (which uses ACP to synthesize malonyl-ACP) and
the post-FASII termination enzyme PlsX (which catalyses the
reversible formation of acyl-phosphate from acyl-ACP)43,50.
Lower FabD activity would leave more ACP available for
PlsX, to drive the reaction towards the synthesis of long-chain
acyl-ACP (the phospholipid synthesis precursor) from exogenous
fatty acids, and thus lead to FASII bypass (Fig. 8). At present, this
or other roles for long-chain acyl-ACP, for example, in
modulating FASII enzyme activities, need to be demonstrated.
Previous results showing that fatty acid auxotrophs carrying
mutations in acc genes are avirulent led to the hypothesis that
FASII-bypass mutants would not survive in the host27,32. In
contrast, we have shown here that the fabDmutants DepTR-5 and
CondTR-17 are infectious and persist in the host, and that clinical
isolates chosen as bearing FabD196 polymorphisms can bypass
FASII inhibition (Fig. 6 and Table 2). We speculate that this
apparent discrepancy may be due to the different effects of the acc
and fabD mutations on malonyl-ACP pools. FapR is a
transcriptional repressor of FASII genes and of phospholipid
synthesis genes plsX and plsC51 (Supplementary Fig. 1). FapR
activity is alleviated by malonyl-CoA51–53. Mutations in acc
leading to reduced synthesis of malonyl-CoA would result in
FapR-mediated repression of phospholipid synthesis. On the
contrary, malonyl-CoA would not be affected in the fabD
mutants; it is even possible that the fabD mutants may
accumulate malonyl-CoA, thus alleviating FapR-mediated
repression of phospholipid synthesis genes. This situation
would favour FASII bypass in environments rich in fatty acids.
The present study uncovered fabD mutants as conferring a
potentially non-deleterious anti-FASII escape strategy. It is
possible that fabD mutations were not identiﬁed previously
because of differences in experimental conditions, for example, in
the choice of fatty acids and/or FASII inhibitors used in
selections. Alternatively, strains might differ in their capacity to
mediate FASII-bypass via mutations. Nevertheless, identiﬁcation
of fabD variant strains belonging to CC5, CC8, and ST59 groups
and including MRSA isolates suggests that FASII-bypass variants
may emerge in these dominant lineages.
Our study revealed that FASII bypass mutants need not be
fatty-acid auxotrophs. The CondTR mutant is resistant to several
FASII inhibitors, yet grows normally and is infectious, indicating
a gain of function. CondTR-like variants may thus present a risk
of dissemination in the environment. The three tested clinical and
commensal isolates with fabD196 polymorphisms were all anti-
FASII resistant (Table 2). Among them, differential anti-FASII
resistance of closely related ST59 strains SA40 (resistant) and
SA957 (sensitive) that differ in fabD196 further supports a role for
fabD in FASII bypass among natural isolates. As FabD ORFs in
genome-sequenced isolates are highly conserved within clonal
types, we speculate that polymorphisms associated with FASII
bypass arose by in vivo selection, possibly due to intensive use of
triclosan in hygiene and household products12. A recent study of
nasal secretions correlated the presence of triclosan with a greater
incidence of colonizing S. aureus and consequent infection risk18.
Interestingly, nasal secretions are fatty-acid-rich54, and the
presence of triclosan or other FASII inhibitors could select for
high frequency FASII bypass. The CondTR-like human nasal
MRSA isolate (SA40) may be a case in point.
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Figure 7 | Shift in ACP species in strains with fabD196 polymorphisms.
The impact of an altered amino acid at FabD position 196 on acyl-ACP pools
was tested by comparing strain pairs: Newman and CondTR-17 (G196 and
R196 respectively), and the ST59 pair SA957 (virulent) and SA40 (nasal
isolate)45 (G196 and S196 respectively). Extracts prepared from 4h
cultures in BHI-FA-T medium were run on conformation-sensitive gels.
Anti-ACP antibodies were used to identify ACP moieties after gel transfer.
In these gels, migration of acyl-ACP species increases with longer acyl
chain length46,66. DTT treatment reduces acyl-ACP thioesters and releases
free ACP47; the DTT-treated Newman protein extract from BHI-grown cells
was used as migration control. Short-chain acyl-ACP is predominant in
reference strains, and long-chain acyl-ACP moieties (arrows) are detected
only in extracts of fabD variants. Results of fatty acid proﬁles of reference
strains and fabD variants are indicated below respective lanes. Nwmn,
Newman strain; *, fatty acid proﬁles derived from non-growing cultures. The
Western is from a single gel with the same exposure, and results are
representative of 3 biologically independent experiments. The Western blot
shown above corresponds to the entire gel.
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Figure 8 | Model of FASII bypass by S. aureus fabD196 variants based on
competition for ACP. A role for FabD in ACP balance and as a determining
factor of FASII bypass is proposed. Indicated pathways and regulatory
functions are as previously identiﬁed43,67. In grey, the inhibited FASII
elongation pathway. FASII initiation enzyme FabD uses ACP and malonyl-
CoA to synthesize malonyl-ACP50. In FASII inhibitory conditions, PlsX
would compete for ACP pools to convert exogenous fatty acids (turquoise)
into phospholipids. Less efﬁcient activity of FabD196 variants (Fig. 7) would
leave ACP available for the PlsX reaction in the indicated direction (PlsX is a
potentially reversible enzyme43), as indicated by orange dashed arrow. Fak-
PlsY and Fak-PlsX-PlsC as proposed here, mediate acyl group joining
respectively to positions 1 and 2 of the glycerol-3-phosphate (G3P)
backbone31,43. FA, fatty acid; FA-ACP, acyl-ACP; FA-PO4, acyl-phosphate.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12944
8 NATURE COMMUNICATIONS | 7:12944 |DOI: 10.1038/ncomms12944 |www.nature.com/naturecommunications
DepTR-like mutants are also likely to be relevant to infection.
Results presented here indicate that DepTR-5 persists in the
kidney over a six-day infection period (Fig. 6), indicating that
these bacteria survive in the infected host. A recent study
identiﬁed a FASII defect among clinical S. aureus small colony
variants (SCV). SCV growth was restored to normal by fatty acid
supplementation55, strongly pointing to a DepTR-like phenotype
and implicating FASII bypass in chronic infection. Similar
ﬁndings were reported for the opportunist pathogen
Enterococcus faecalis56. Abscess formation during S. aureus
infection is common, and it is tempting to speculate that this
stage of infection may give privileged access to host fatty acids
that support growth of both CondTR and DepTR mutants.
Fatty-acid-rich skin36,57, possibly enriched by fatty-acid-
containing skin products58, may be an ideal medium on which
FASII inhibitors would select for FASII-bypass-competent
staphylococci. The selection strategy used in our study
mimicked this situation. Emergence of versatile S. aureus FASII
bypass variants upon anti-FASII treatment may generate a long-
term risk for persistence and infection59, requiring new rounds of
antimicrobial therapy.
Methods
Bacterial strains and growth conditions. Experiments were performed using the
S. aureus Newman strain60. SA40 (an Asian-Paciﬁc nasal ST59 MRSA isolate from
a healthy child) and SA957 (a virulent Taiwan ST59 blood isolate) were kindly
provided by Freidrich Go¨tz and Regine Stemmler (U. Tu¨bingen, Germany)45.
The M0251 (MRSA, clonal complex CC5) and M1532 strains are respectively nasal
and sputum isolates that were generously provided by Mary Delaney and Michael
Calderwood, and are part of the Brigham and Women’s Hospital collection
(Boston, USA). Plasmid cloning and extraction were performed in E. coli strains
Top10 (Invitrogen, France) and MG1655 (ref. 61). BHI and LB media were used for
S. aureus, and LB for E. coli growth. The fatty-acid mixture (referred to as ‘FA’)
comprises C14:0 (myristic acid), C16:0 (palmitic acid), and C18:1 (oleic acid);
100mM stocks in dimethylsulphoxide (DMSO) of each fatty acid were mixed at a
1:1:1 ratio, and then diluted 1:200 for use in liquid or solid medium. Other fatty
acid mixtures were prepared similarly, such that the ﬁnal molar concentration of
fatty acids was 0.5mM (that is, 0.17mM each fatty acid). All fatty acids were from
Larodan Fine Chemicals (Sweden). Newborn calf serum (Sigma-Aldrich, France)
and delipidated calf serum (Eurobio, France) were added to growth medium
(10% ﬁnal concentration) as indicated. Triclosan (Irgasan; Sigma-Aldrich) was
routinely used at 0.25 mg per mL in liquid cultures; this is 15 times the MIC for
S. aureus Newman strain in BHI medium. Platensimycin (Tebu-Bio, France)
and AFN-1252 (MedChem Express) were used respectively at 2 mgml 1 and
80 ngml 1 as per published efﬁcacies11,27. Anti-FASII drugs were prepared
in DMSO.
Kidney and liver extracts from adult pigs (usually 6 months, purchased at a
local butcher shop) were prepared as follows: 200 g of each organ were cut in
0.5 cm cubes, and resuspended in PBS (1:2 w-v). Samples were homogenized using
an ultra-turrax and then centrifuged twice (4,000 g for 30min) to remove solid
material. Supernatants were ﬁltered through Whatman paper, recentrifuged at
20,000 g, and then sterile-ﬁltered sequentially on 0.45 and 0.2 micron membranes.
All steps were performed at 4 C, and extracts were stored at  20 C.
Selection for triclosan resistance on FA plates. Dilutions of overnight S. aureus
Newman cultures were plated on four types of medium: non-selective (BHI); BHI
plus FA (BHI-FA; FA are as described above); BHI with triclosan (BHI-T
(0.25 mgml 1)), BHI containing FA and triclosan (BHI-FA-T (0.25 mgml 1)).
Plates were incubated at 37 C and scored at 48 h. Colonies were selected for
phenotypic conﬁrmation and characterization.
Colony forming units (CFU) on plates were compared with determine FA-TR
frequencies. Colonies that appeared on BHI-FA-T plates were then patched on the
four plates as above to distinguish mutational phenotypes. Proportions of DepTR
and CondTR mutants varied in independent experiments, possibly suggesting that
slight variations in conditions may impact mutant phenotypes. Changes in fatty
acid proﬁles of some FA-TR isolates were observed upon FA-T selection,
particularly after storage, suggesting that adaptation might occur during selection
and/or storage. Care was therefore taken in analysing proﬁles directly from
selective plates and before storage.
Determination of fatty acid proﬁles. Whole cell esteriﬁed fatty acid determi-
nations were done essentially as described62. Brieﬂy, 1–2ml S. aureus cultures
(OD600¼Z1) were centrifuged, washed once in 0.9% NaCl containing 0.02%
Triton X-100, then washed twice in 0.9% NaCl. Cell pellets were treated with 0.5ml
of 1N sodium methoxide. Heptane (200 ml) was then added, together with methyl-
10-undecenoate (Sigma-Aldrich) as internal standard, vortexed for 1min, and
centrifuged. Fatty acid methyl esters were recovered in the heptane phase. Analyses
were performed in a split-splitless injection mode on an AutoSystem XL Gas
Chromatograph (Perkin-Elmer) equipped with a ZB-Wax capillary column
(30m 0.25mm 0.25mm; Phenomenex, France). Data were recorded and
analysed by TotalChrom Workstation (Perkin-Elmer). S. aureus fatty acid peaks
were detected between 12 and 30min of elution.
DNA sequencing. The fabI, accABCD and fabD genes of selected S. aureus
Newman strain FA-TR clones were sequenced. Primer pairs used for DNA
ampliﬁcation were: for fabI: FabIfd 50-GATACAGAAAGGACTAAATCAAA-30
and FabIrev 50-TTTCCATCAGTCCGATTATTATA-30 (ref. 20); for accDA:
AccDAfd 50-AACTAATGTATTGAATTGATGTAAACG-30 and AccDArev
50-AACATTCAACAGTCAAACGA-30 ; for accBC: two sets were used AccBC1fd
50-ACGGGTAGATGAAAACAAAC-30 and AccBC1rev 50-TCTTTTTCATCACG
AGCAA-30 , and AccBC2fd 50-AGTTGTTCCTGGTAGTGACG-30 and AccBC2rev
50-CCAGTGATGCCTTCGACTTC-30 ; for fabD: FabDfd 50-GAAGGTACTG
TAGTTAAAGCACACG-30 and FabDrev 50-GCTTTGATTTCTTCGACTAC
TGCTT-30.
Whole genome sequencing was done on DepTR isolates DepTR-5, DepTR-72
and DepTR-45, CondTR mutant CondTR-17, and our parental Newman strain.
Libraries were prepared with genomic DNA using the Illumina MiSeq next
generation sequencing system (IMGM, Germany). The 2 250 base pair reads
were aligned and sequence variations were analysed using CLC Genomics
Workbench 5.5.2 software (CLC Bio). SNPs were found when comparing our
control Newman strain to that in the Newman reference sequence (GenBank
Nucleotide accession code NC_009641). Only differences between our laboratory
Newman strain and FA-TR mutants were considered in genome comparisons.
Cloning of fabD and acpP. The fabD gene (locus NWMN_1140) and the
fabDG196R variant gene were PCR-ampliﬁed from chromosomal DNA prepared
from the Newman strain using the forward primer fabD-tail-F (50-ATAAGC
CGGGGGATCCACTAATGAGTAAAACAGCAATTATTTTTCCGGG -30) and
reverse primer fabD-tail-R (50-GCGCGCAATTAACCCTCACTAAAGGGTTA
GTCATTTTCATTC CATCCTTTCACATC-30). Ampliﬁed DNA was cloned by
Gibson assembly63. The vector, pJIM2246-ptetR64, was ampliﬁed for fabD cloning
using primers pJ-fabD-R (50-CCCGGAAAAATAATTGCTGTTTTACTCAT
TAGTGGATCCCCCG GCTTAT-30) and pJ-fabD-F (50-GATGTGAAAGGAT
GGAATGAAAATGACTAACCCTTTAGTGAGGGTTAATTGC GCGC-30).
Ligations were initially transformed into E. coli Top10. After plasmid veriﬁcation
by DNA sequencing, plasmids with and without inserts were transformed by
electroporation into S. aureus strain RN4220 (ref. 60), re-extracted and
transformed into Newman WT and fabD mutants. Standard electroporation
protocols were followed65, except that DepTR-5 competent cells were prepared in
BHI medium containing 10% heat-inactivated newborn calf serum and FA.
The acpP gene (locus NWMN_1142) was cloned in plasmid pMalC4X (New
England Biolabs) as a fusion to mbp. Brieﬂy, acpP was PCR-ampliﬁed using
forward primer 50-GCGAATTCGAAAATTTCGATAAAGTAAAAGATATC-30
and reverse primer 50-GGGAAGCTTTTATTTTTCAAGACTGTTAATAA
ATTTAAC-30 . The digested fragment was then ligated to EcoRI-HindIII-linearized
pMalC4X, and cloned in E. coli TG1, giving plasmid pMalC4X-acpP.
Complementation tests. Overnight cultures of wild type and fabD mutant strains
carrying plasmids pJ or pJ-fabD were used to inoculate cultures at a starting density
of OD600¼ 0.05, in the following media: (i) LB containing 3 mgml 1 Cm and
50 ngml 1 anhydrotetracycline (ATc), (ii) same as (i) plus 10% kidney extract
and (iii) same as (ii) plus 0.5 mgml 1 triclosan. Growth was monitored in three
independent experiments. Growth lags of DepTR-5 (pJ-fabD) in condition
(iii) compared with DepTR-5 (pJ), and of CondTR-17 (pJ-fabD) compared with
CondTR-17 (pJ) were determined as a ratio in individual experiments, and plotted
as the ratio of the OD600 values at different time points (Supplementary Fig. 5).
WT and fabD mutant resistance to FASII inhibitors. WT, DepTR-5 and
CondTR-17 strains were grown overnight in BHI-FA, washed twice in BHI, and
100 ml of OD600¼ 0.1 bacterial suspension were plated on solid BHI or BHI-FA
medium to obtain a lawn. Triclosan (1.5 mg in 3 ml), AFN-1252 (1mg in 3 ml), and
platensimycin (8mg in 4 ml) were spotted immediately after plating. Plates were
incubated at 37 C and photographed after 48 h. Colonies growing within the
inhibition zone of the anti-FASII drugs were patched to BHI, or to BHI-FA media
containing or not triclosan 0.25 mgml 1, or AFN-1252 0.08 mgml 1, and scored
for growth after 48 h. Bacterial patches were harvested directly for fatty acid proﬁle
evaluation.
Mouse infection model. Overnight cultures of DepTR-5, CondTR-17 and WT
strains were grown in BHI-FA containing 10% serum. The morning of infection
they were diluted to obtain a starting OD600¼ 0.02 (WT and CondTR-17) and 0.04
(DepTR-5). Cells were grown in the same medium to OD600¼ 1, washed, and
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resuspended in 0.9% NaCl to obtain 2 106 cells per mL, as conﬁrmed by plating
on BHI-FA plus 10% serum solid medium. Six-week female BALB/c mice
(Janvier Labs, France) were injected in the tail vein with 106 cells in 500ml 0.9%
NaCl (8–11 animals per group). Animals were sacriﬁced at day 2 and day 6
(4–6 animals per time point) and dissected. Liver and kidneys were suspended in
phosphate-buffered saline and homogenized with an ultra-turrax. CFUs were
determined per organ type on BHI-FA plates containing 10% serum. DepTR-5 and
CondTR-17 clones (20 for each mutant per organ), issued from day 6 platings, were
randomly selected to verify fatty-acid-dependent and conditional phenotypes;
conservation of the mutated alleles was further conﬁrmed in two clones from each
organ by PCR-sequencing. The presented data are pooled from animal studies
performed as two independent experiments.
Statistical analyses. The Mann–Whitney U-test was used to evaluate whether
differences in CFUs in mice infected by Newman or mutant derivatives were
statistically signiﬁcant. Differences were compared for day 2 or day 6 between
Newman and mutant derivatives. Analyses were performed with GraphPad Prism
Software Version 6.00 (GraphPad Software, USA). Statistical signiﬁcance was given
as P values.
Growth capacity of fabD clinical variants and mutants on FA-triclosan. Pre-
cultures of Newman, M0251, M1532, SA957, SA40, CondTR-4, and CondTR-17
strains were prepared in BHI medium, and used to inoculate BHI or BHI-FA-T
medium at an initial OD600¼ 0.01. Cell density was determined as OD600 measure-
ments after 16 h growth. FA proﬁles were determined for cultures that reached OD600
values above 0.5, which was deﬁned as the growth threshold. Experiments were
repeated three times.
ACP assessment by conformation-sensitive gels. Anti-S. aureus-ACP anti-
bodies were prepared using ACP puriﬁed from E. coli TG1 carrying pMalC4X-
acpP. For this purpose, cultures were grown in LB ampicillin (100 mgml 1), and
ACP-MBP expression was induced by IPTG 0.5mM for 2 h during mid-expo-
nential growth. The ACP-MBP fusion was recovered on a maltose resin and eluted
with 20mM maltose. The fusion protein was digested with Xa protease as per
manufacturer’s instructions (New England Biolabs). Puriﬁed ACP was recovered
from polyacrylamide gel electrophoresis–SDS (PAGE–SDS) gels and used for
rabbit antibody preparation (Covalabs). The antibody preparation was validated on
puriﬁed ACP protein, and used at 1:15,000 dilution.
Conformation-sensitive (non-denaturing) gels were done as described27,46.
Precultures of test strains were grown to OD600¼ 0.5 in BHI medium at 37 C.
They were then split in equal aliquots, and further grown for 4 h in BHI or
BHI-FA-T. Cultures were harvested for preparation of protein extracts as
described27 from the equivalent of OD600¼ 5. DTT-treated extracts from
BHI-grown S. aureus Newman were used as reference for the position of
holo-ACP27,47. Samples (equivalent to OD600¼ 0.25 in 10ml) were loaded on 13%
polyacrylamide gels containing 1M urea, which were run at 100 volts for 3 h, and
then transferred to PVDF membranes (0.2 mm; BioRad) for Western blotting and
exposure using an ECL kit (Perkin-Elmer) as per supplier’s instructions.
Ethics statement. Animal experiments were performed at the animal facilities of
HUPC in strict accordance with European Union guidelines for handling of
laboratory animals, approved by the Ethics Committee for Animal Experimenta-
tion at the University of Paris-Descartes (CEEA 34), registration number 14-077.
Data availability. Genome sequence data for DepTR-5, DepTR-72, DepTR-45,
CondTR-17, and our parental Newman strain have been deposited in the European
Nucleotide Archive and can be accessed at http://www.ebi.ac.uk/ena/data/view/
PRJEB11476. The authors declare that all other data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or
from the corresponding author upon request.
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